deltatrials
Completed PHASE2 NCT00004013

Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer

Treatment of Refractory Stage IV Metastatic Breast Cancer With Weekly Paclitaxel or Weekly Paclitaxel and Herceptin Following Autologous/Syngeneic Stem Cell Transplant

Sponsor: Fred Hutchinson Cancer Center

Conditions Breast Cancer
Interventions paclitaxel trastuzumab
Updated 6 times since 2017 Last updated: Mar 31, 2010 Started: Jan 31, 1999 Primary completion: Oct 31, 2001 Completion: Oct 31, 2001

Listed as NCT00004013, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jan 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seattle, United States